Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Illinois Cancercare, PC

Neither a doctor nor a teaching hospital

Research payments

$1,201,764

64 payments

Through program year 2025, Illinois Cancercare, PC is reported as receiving $1,201,764 in research payments, across 64 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $600,486 20
2024 Research $164,640 10
2023 Research $83,159 5
2022 Research $62,528 9
2021 Research $100,831 8
2020 Research $142,314 8
2019 Research $47,808 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $664,076 32 payments
  2. Celgene Corporation $338,517 17 payments
  3. AstraZeneca UK Limited $135,532 4 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $22,767 6 payments
  5. Acerta Pharma LLC $21,276 3 payments
  6. Ipsen Bioscience Inc $19,500 1 payment
  7. Merck Sharp & Dohme Corporation $96 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) $373,181 14 payments
  2. Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) $197,743 2 payments
  3. A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia $114,802 3 payments
  4. Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry: The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and tr $82,422 2 payments
  5. Connect MM- The Multiple Myeloma Disease Registry $60,375 5 payments
  6. Celgene Connect Myeloid Disease Registry $48,125 1 payment
  7. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. $43,750 1 payment
  8. Celgene - Connect MDS/AML $34,611 1 payment
  9. Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices $32,416 3 payments
  10. Connect MDS/AML $30,484 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record